Microviable Therapeutics Announces 1.5 Million Euros Investment to Advance the Company´s Microbiota-Derived Biotherapeutic Products
19.4.2022 12:00:00 EEST | Business Wire | Press release
Microviable Therapeutics SL, a preclinical stage biotechnology company developing orally administered biological drugs based on microbiota-derived products, announced 1.5 million euros seed funding from the private medical group Inmunomet Intolerancia y Disbiosis SL.
Microviable will use the seed funding to enhance their therapeutic development platform and advance their pipeline to the clinical stage. The lead product, MVT-201, is under evaluation at pre-clinical stage with positive results, and it is an unique in its kind biological drug based on complete microbiota (HiPMTM) for undisclosed targets. The microbiota-derived product development platform also includes rationally design and defined bacterial consortia that will be advanced with this funding.
This investment will enable to consolidate Microviable’s growth and focus towards the therapeutics, while increasing their facilities and headcount.
“We are really excited for Microviable´s future and grateful for this opportunity to bring novel solutions to healthcare with the ultimate goal of improving the patients’ quality of life”, said Claudio Hidalgo Cantabrana, PhD, co-founder and CEO at Microviable. “We wanted a strategic partner that shares our vision of using microbiota-derived biological drugs to treat patients while providing smart capital, and Inmunomet fulfills all of our expectations”.
Inmunomet is a private medical group specialized in intolerances and gut dysbiosis related disorders with strong experience on the clinic. With this investment, Inmunomet is seeking to be part of Microviable´s growth being ahead on the development of novel solutions based on microbiota-derived biotherapeutic products. Inmunomet provides not only the funding but smart capital and synergies on the clinic, very well aligned with Microviable focus and providing access to the real-world clinical needs to address unmet challenges in human health.
About Microviable
Microviable Therapeutics SL, spun out from the Spanish National Research Council in 2016, focused on developing novel technologies and therapeutic products from the microbiota. Over the last years, Microviable lunched a disruptive product for microbiota sampling that has grown exponentially into an international market with clients across fifteen different countries. Moreover, it has developed a unique technology to store human microbiota for downstream therapeutic applications. Currently, Microviable’s platform together with its large and diverse proprietary bacterial culture collection, has enabled the development of two different products, a unique in its kind product of complete microbiota and rationally defined bacterial consortia.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005270/en/
Contact information
Claudio Hidalgo Cantabrana, PhD
claudio.hidalgo@microviable.com
(+34)670034435
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Khimji Ramdas Group Chooses Rimini Street to Reduce SAP Support Costs, Protect 700+ Customizations and Reinvest Savings in Innovation6.8.2026 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that Khimji Ramdas Group, one of Oman’s largest privately held conglomerates, has selected Rimini Support™ for SAP, a move that has helped the organization reduce costs, reinvest savings in AI innovation and maintain its highly customized SAP ECC 6 environment with zero downtime. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806244148/en/ Khimji Ramdas Group Chooses Rimini Street to Reduce SAP Support Costs, Protect 700+ Customizations and Reinvest Savings in Innovation “Staying on SAP ECC is a strategic decision for us,” said Prashant Kumar, CTO, Khimji Ramdas Group. “We went to an industry analyst to ask what options we have to keep our ECC systems running without vendor support dependencies, and they suggested that we contact Rimini Stree
AM Best Upgrades Fortegra Insurance Subsidiaries to A (Excellent)6.8.2026 16:00:00 EEST | Press release
The Fortegra Group, Inc. (“Fortegra” or the “Company”), a global specialty insurer and part of DB Insurance Co., Ltd., today announced that AM Best has upgraded the Financial Strength Rating (FSR) of its insurance subsidiaries to A (Excellent) from A- (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) to “a” (Excellent) from “a-” (Excellent). The outlook assigned to the ratings is stable, and AM Best removed the ratings from under review with positive implications. KBRA has also upgraded all of its ratings for the Company. The upgrade applies across Fortegra’s insurance platform. The property and casualty companies include Lyndon Southern Insurance Company, Insurance Company of the South, Response Indemnity Company of California, Blue Ridge Indemnity Company, Fortegra Specialty Insurance Company and Fortegra Europe Insurance Company SE. The life and health companies include Life of the South Insurance Company, Bankers Life Insurance Company of Louisiana and Southern F
Naser Taher, Chairman and Founder of MultiBank Group, Honored by H.H. Sheikh Nahyan bin Mubarak Al Nahyan with the Golden Excellence Award for FinTech, Digital Asset and Blockchain Excellence6.8.2026 15:53:00 EEST | Press release
Naser Taher, Chairman and Founder of MultiBank Group, has been honored with the Golden Excellence Award for FinTech, Digital Asset and Blockchain Excellence at the 9th Golden Excellence Awards 2026. The award was presented by H.H. Sheikh Nahyan bin Mubarak Al Nahyan, UAE Cabinet Member and Minister of Tolerance & Coexistence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806828617/en/ Naser Taher, Chairman and Founder of MultiBank Group, Honored by H.H. Sheikh Nahyan bin Mubarak Al Nahyan with the Golden Excellence Award for FinTech, Digital Asset and Blockchain Excellence. The recognition reflects MultiBank Group’s continued expansion into regulated digital assets through mb.io, the Group’s VARA-regulated cryptocurrency exchange. Through mb.io, clients can access crypto spot trading, including the Group’s global ecosystem utility token, $MBG, alongside seamless on- and off-ramp solutions and high-volume trading through
Mary Kay’s Pink Changing Lives ® Program Turns Purpose Into Measurable Impact for Women Around the World6.8.2026 15:05:00 EEST | Press release
Mary Kay Inc., a global advocate for women’s empowerment, proudly reaffirms its commitment to enriching women’s lives worldwide through its signature Pink Changing Lives® Program – a multi-faceted global initiative that blends purpose-driven giving with cause-marketing to create meaningful, measurable impact across communities. Since 1996, the program has provided over $230 million in monetary and product donations to nonprofit organizations empowering women, transforming women’s health and safety, and protecting our natural resources. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806671194/en/ Mary Kay China supports the Hope for Pearl Program, providing financial assistance to girls from economically disadvantaged areas to receive a life-changing education, opening doors to new possibilities and bright futures. (Photo Courtesy: Mary Kay China) Rooted in the Company’s mission of enriching women’s lives, the Pink Changin
Omilia Secures $67 Million in Series B Funding to Accelerate Global Expansion of Its Agentic Self-Learning CX Platform for Large Enterprises6.8.2026 15:00:00 EEST | Press release
Omilia, the Self-Learning Agentic CX company trusted by many of the world's largest enterprises, today announced a $67 million Series B funding round led by transatlantic software & AI specialist, Expedition Growth Capital. Omilia builds Agentic CX for the world's largest and most demanding enterprises – organizations often in regulated industries such as banking, insurance and healthcare, where security, scalability and cost predictability are non-negotiable. Its customers include Capital One, Discover, RBC, Taco Bell, DWP and PSEG. The company's voice-first AI platform, honed over more than 200 enterprise deployments, is built entirely on its own proprietary agentic Voice AI technology, and supports the most stringent enterprise security and compliance standards, including FedRAMP, PCI-DSS, SOC 2, HIPAA and GDPR. Omilia runs some of the largest agentic voice deployments in production today. These include a Tier 1 US bank handling well over 1 million calls per day, and one of the worl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom